Literature DB >> 29085701

Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Indsey Kennedy1,2, Heather Francis1,2,3, Fanyin Meng1,2,3, Shannon Glaser1,2,3, Gianfranco Alpini1,2,3.   

Abstract

Cholangiopathies are a group of rare, devastating diseases that arise from damaged cholangiocytes, the cells that line the intra- and extra-hepatic bile ducts of the biliary epithelium. Cholangiopathies result in significant morbidity and mortality and are a major cause of liver transplantation. A better understanding of the underlying pathogenesis that influences cholangiocyte dysregulation and cholangiopathy progression is necessary, considering the dismal prognosis associated with these diseases. MicroRNAs are a class of small, non-coding RNAs that regulate post-transcriptional mRNA expression of specific genes. The role of microRNAs has expanded to include the initiation and development of many diseases, including cholangiopathies. Understanding microRNA regulation of cholangiopathies may provide diagnostic and therapeutic benefit for these diseases. In this review, the authors primarily focus on studies published within the last five years that help determine the diagnostic and therapeutic potential of microRNAs in cholangiopathies.

Entities:  

Keywords:  Cholangiopathies; Diagnosis; Therapy; microRNAs

Year:  2017        PMID: 29085701      PMCID: PMC5659325          DOI: 10.1016/j.livres.2017.03.003

Source DB:  PubMed          Journal:  Liver Res


  99 in total

Review 1.  Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood.

Authors:  G Maggiore; S Riva; M Sciveres
Journal:  Minerva Gastroenterol Dietol       Date:  2009-03

2.  Anti-tumoral effects of miR-3189-3p in glioblastoma.

Authors:  Duane Jeansonne; Mariacristina DeLuca; Luis Marrero; Adam Lassak; Marco Pacifici; Dorota Wyczechowska; Anna Wilk; Krzysztof Reiss; Francesca Peruzzi
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

Review 3.  Systematic review: the pathophysiology and management of polycystic liver disease.

Authors:  F Temmerman; L Missiaen; B Bammens; W Laleman; D Cassiman; C Verslype; J van Pelt; F Nevens
Journal:  Aliment Pharmacol Ther       Date:  2011-07-26       Impact factor: 8.171

4.  Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis.

Authors:  Jeanine Ward; Chitra Kanchagar; Isana Veksler-Lublinsky; Rosalind C Lee; Mitchell R McGill; Hartmut Jaeschke; Steven C Curry; Victor R Ambros
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

5.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

6.  MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.

Authors:  Seung-Ok Lee; Tatyana Masyuk; Patrick Splinter; Jesús M Banales; Anatoliy Masyuk; Angela Stroope; Nicholas Larusso
Journal:  J Clin Invest       Date:  2008-10-23       Impact factor: 14.808

Review 7.  Biliary atresia: pathogenesis and treatment.

Authors:  M D Bates; J C Bucuvalas; M H Alonso; F C Ryckman
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

Review 8.  Th17 cells in autoimmune and infectious diseases.

Authors:  José Francisco Zambrano-Zaragoza; Enrique Jhonatan Romo-Martínez; Ma de Jesús Durán-Avelar; Noemí García-Magallanes; Norberto Vibanco-Pérez
Journal:  Int J Inflam       Date:  2014-08-03

Review 9.  Cancer and liver cirrhosis: implications on prognosis and management.

Authors:  Matthias Pinter; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  ESMO Open       Date:  2016-03-17

10.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

View more
  5 in total

1.  MicroRNAs and cholangiocarcinoma: elucidating the effects of tiny giants.

Authors:  Vik Meadows; Heather Francis
Journal:  AME Med J       Date:  2018-10-04

2.  MicroRNA-499 rs3746444 polymorphism in Egyptian children with biliary atresia.

Authors:  Eman Gawish; Elhamy Abd El-Monem; Mona El-Abd; Gihan Ahmed Sobhy; Heba Ghanem
Journal:  Clin Exp Hepatol       Date:  2020-09-30

Review 3.  Biomarkers for primary biliary cholangitis: current perspectives.

Authors:  Elias Kouroumalis; Demetrius Samonakis; Argyro Voumvouraki
Journal:  Hepat Med       Date:  2018-06-18

Review 4.  Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma.

Authors:  Christian Prinz; Robin Frese; Mashiba Grams; Leonard Fehring
Journal:  Genes (Basel)       Date:  2022-08-19       Impact factor: 4.141

5.  Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction.

Authors:  Tong-Hong Wang; Chuen Hsueh; Chin-Chuan Chen; Wan-Syuan Li; Chau-Ting Yeh; Jang-Hau Lian; Junn-Liang Chang; Chi-Yuan Chen
Journal:  Int J Mol Sci       Date:  2018-09-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.